Press Releases

Today, the U.S. Food and Drug Administration and the National Institutes of Health (NIH) announced the launch of the Critical Path for Rare Neurodegenerative Diseases (CP-RND)—a public-private partnership aimed at advancing the understanding of neurodegenerative diseases and fostering the development of treatments for amyotrophic lateral sclerosis (ALS) and other rare neurodegenerative diseases.

Researchers have published two papers describing how they identified a potential new pathway for treating a sporadic form of amyotrophic lateral sclerosis (ALS). The studies were published as part of a cooperative research agreement between the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health, and the Switzerland-based biotechnology company GeNeuro Inc.

A study funded by the National Institutes of Health found that biomarkers present in the blood on the day of a traumatic brain injury (TBI) can accurately predict a patient’s risk of death or severe disability six months later. Measuring these biomarkers may enable a more accurate assessment of patient prognosis following TBI, according to results published today in Lancet Neurology. 

To continuously improve the quality of research funded by the National Institutes of Health, five new grants will launch the Initiative to Improve Education in the Principles of Rigorous Research. This program will create an educational platform containing various training modules covering different aspects of scientific rigor—the strict application of the scientific method to ensure robust, unbiased research.

A study from the National Institutes of Health describes the immune response triggered by COVID-19 infection that damages the brain’s blood vessels and may lead to short- and long-term neurological symptoms.

Researchers have identified two types of cells in our brains that are involved in organizing discrete memories based on when they occurred.

Researchers from two independent research teams have discovered how the mislocalization of a protein, known as TDP-43, alters the genetic instructions for UNC13A, providing a possible therapeutic target that could also have implications in treating amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other forms of dementia.

Using an experimental drug, researchers were able to suppress a mutated amyotrophic lateral sclerosis (ALS) gene.

SARS-CoV-2 was initially identified as a respiratory virus, but it can affect the entire body, including the nervous system.

In a small study, researchers funded by the National Institutes of Health captured more than 1,000 hours of brain recordings from patients with OCD in the clinic and at home.